No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
US OptionsDetailed Quotes
AKRO241220C40000
- 0.02
- 0.000.00%
15min DelayClose Dec 20 16:00 ET
0.00High0.00Low
0.00Open0.02Pre Close0 Volume110 Open Interest40.00Strike Price0.00Turnover0.00%IV43.13%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier-10DDays to Expiry0.02Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma1398.00Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Intraday
- 5D
- Daily
News
Evercore Maintains Akero Therapeutics(AKRO.US) With Buy Rating, Maintains Target Price $38
Possible Bearish Signals With Akero Therapeutics Insiders Disposing Stock
Akero Therapeutics to Present at the 7th Annual Evercore ISI HealthCONx Conference
Akero Therapeutics Receives Buy Rating for Promising Efruxifermin Developments in MASH Treatment
Akero a New Buy at Citi on Liver Disease Asset
Akero Therapeutics Price Target Announced at $65.00/Share by Citigroup